HEADER                                            01-JUN-22                     
TITLE     ALPHAFOLD MONOMER V2.0 PREDICTION FOR UNCHARACTERIZED PROTEIN         
TITLE    2 (A0A2U9ICS3)                                                         
COMPND    MOL_ID: 1;                                                            
COMPND   2 MOLECULE: UNCHARACTERIZED PROTEIN;                                   
COMPND   3 CHAIN: A                                                             
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 ORGANISM_SCIENTIFIC: ACIDIANUS BRIERLEYI;                            
SOURCE   3 ORGANISM_TAXID: 41673                                                
REMARK   1                                                                      
REMARK   1 REFERENCE 1                                                          
REMARK   1  AUTH   JOHN JUMPER, RICHARD EVANS, ALEXANDER PRITZEL, TIM GREEN,    
REMARK   1  AUTH 2 MICHAEL FIGURNOV, OLAF RONNEBERGER, KATHRYN TUNYASUVUNAKOOL, 
REMARK   1  AUTH 3 RUSS BATES, AUGUSTIN ZIDEK, ANNA POTAPENKO, ALEX BRIDGLAND,  
REMARK   1  AUTH 4 CLEMENS MEYER, SIMON A A KOHL, ANDREW J BALLARD,             
REMARK   1  AUTH 5 ANDREW COWIE, BERNARDINO ROMERA-PAREDES, STANISLAV NIKOLOV,  
REMARK   1  AUTH 6 RISHUB JAIN, JONAS ADLER, TREVOR BACK, STIG PETERSEN,        
REMARK   1  AUTH 7 DAVID REIMAN, ELLEN CLANCY, MICHAL ZIELINSKI,                
REMARK   1  AUTH 8 MARTIN STEINEGGER, MICHALINA PACHOLSKA, TAMAS BERGHAMMER,    
REMARK   1  AUTH 9 DAVID SILVER, ORIOL VINYALS, ANDREW W SENIOR,                
REMARK   1  AUTH10 KORAY KAVUKCUOGLU, PUSHMEET KOHLI, DEMIS HASSABIS            
REMARK   1  TITL   HIGHLY ACCURATE PROTEIN STRUCTURE PREDICTION WITH ALPHAFOLD  
REMARK   1  REF    NATURE                        V. 596   583 2021              
REMARK   1  REFN                   ISSN 0028-0836                               
REMARK   1  PMID   34265844                                                     
REMARK   1  DOI    10.1038/s41586-021-03819-2                                   
REMARK   1                                                                      
REMARK   1 DISCLAIMERS                                                          
REMARK   1 ALPHAFOLD DATA, COPYRIGHT (2021) DEEPMIND TECHNOLOGIES LIMITED. THE  
REMARK   1 INFORMATION PROVIDED IS THEORETICAL MODELLING ONLY AND CAUTION SHOULD
REMARK   1 BE EXERCISED IN ITS USE. IT IS PROVIDED "AS-IS" WITHOUT ANY WARRANTY 
REMARK   1 OF ANY KIND, WHETHER EXPRESSED OR IMPLIED. NO WARRANTY IS GIVEN THAT 
REMARK   1 USE OF THE INFORMATION SHALL NOT INFRINGE THE RIGHTS OF ANY THIRD    
REMARK   1 PARTY. THE INFORMATION IS NOT INTENDED TO BE A SUBSTITUTE FOR        
REMARK   1 PROFESSIONAL MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT, AND DOES NOT   
REMARK   1 CONSTITUTE MEDICAL OR OTHER PROFESSIONAL ADVICE. IT IS AVAILABLE FOR 
REMARK   1 ACADEMIC AND COMMERCIAL PURPOSES, UNDER CC-BY 4.0 LICENCE.           
DBREF  XXXX A    1   173  UNP    A0A2U9ICS3 A0A2U9ICS3_9CREN     1    173       
SEQRES   1 A  173  MET SER MET LYS PRO LEU ILE LEU GLY ASN ILE ILE SER          
SEQRES   2 A  173  LEU ILE ALA ALA PHE PHE ILE LEU SER ILE LEU PHE LEU          
SEQRES   3 A  173  LEU GLY ILE TYR GLY LEU ASP PHE ALA PHE ASN ASN ILE          
SEQRES   4 A  173  THR LYS ILE LEU MET TRP ILE VAL TRP ILE PHE ALA PHE          
SEQRES   5 A  173  PRO ALA TYR VAL GLU TYR ARG LYS SER SER LEU LYS ALA          
SEQRES   6 A  173  SER TYR LEU ILE ASN TYR LEU PRO PRO ILE ALA ILE LEU          
SEQRES   7 A  173  ILE THR PHE ILE GLY LEU VAL LEU LEU MET GLU GLY LYS          
SEQRES   8 A  173  PHE LEU GLY LEU GLU THR ILE VAL LEU GLY TYR ILE LEU          
SEQRES   9 A  173  GLU PRO ILE SER GLY ILE SER ILE TYR LEU SER ILE LYS          
SEQRES  10 A  173  ASP ILE GLN LYS PHE SER ALA TYR LEU PHE PHE TYR GLY          
SEQRES  11 A  173  ALA VAL ILE TYR THR ILE GLY LEU PRO PHE TYR LEU ILE          
SEQRES  12 A  173  ASN ILE PRO GLU ILE ALA ILE ILE GLY ASP SER ILE LYS          
SEQRES  13 A  173  ILE ILE GLY LEU SER TYR PHE ILE LYS PHE MET ILE LYS          
SEQRES  14 A  173  ASN SER TYR GLN                                              
CRYST1    1.000    1.000    1.000  90.00  90.00  90.00 P 1           1          
ORIGX1      1.000000  0.000000  0.000000        0.00000                         
ORIGX2      0.000000  1.000000  0.000000        0.00000                         
ORIGX3      0.000000  0.000000  1.000000        0.00000                         
SCALE1      1.000000  0.000000  0.000000        0.00000                         
SCALE2      0.000000  1.000000  0.000000        0.00000                         
SCALE3      0.000000  0.000000  1.000000        0.00000                         
MODEL        1                                                                  
ATOM      1  N   MET A   1      10.740  -4.365 -19.787  1.00 81.88           N  
ATOM      2  CA  MET A   1      10.021  -3.628 -18.729  1.00 81.88           C  
ATOM      3  C   MET A   1       9.864  -2.186 -19.176  1.00 81.88           C  
ATOM      4  CB  MET A   1      10.790  -3.727 -17.410  1.00 81.88           C  
ATOM      5  O   MET A   1      10.844  -1.607 -19.627  1.00 81.88           O  
ATOM      6  CG  MET A   1      10.065  -3.053 -16.245  1.00 81.88           C  
ATOM      7  SD  MET A   1      10.776  -3.452 -14.639  1.00 81.88           S  
ATOM      8  CE  MET A   1      12.447  -2.795 -14.817  1.00 81.88           C  
ATOM      9  N   SER A   2       8.653  -1.635 -19.120  1.00 88.00           N  
ATOM     10  CA  SER A   2       8.388  -0.247 -19.513  1.00 88.00           C  
ATOM     11  C   SER A   2       8.522   0.680 -18.304  1.00 88.00           C  
ATOM     12  CB  SER A   2       7.014  -0.131 -20.174  1.00 88.00           C  
ATOM     13  O   SER A   2       7.851   0.488 -17.290  1.00 88.00           O  
ATOM     14  OG  SER A   2       6.818   1.193 -20.628  1.00 88.00           O  
TER      15      GLN A   3                                                      
ENDMDL                                                                          
END                                                                             